louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06113120: Specific Role of Nurse in a Mobile Palliative Care Team (EMSP): Real Autonomy or Utopia
Official title: Specific Role of Nurse in a Mobile Palliative Care Team (EMSP): Real Autonomy or Utopia
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Palliative Care
Keywords: Improving patients care
Nurse
Palliative Care
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-11-02
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: State-certified nurse working in EMSP with intra- and extra-hospital activity in a CHRU or CHU.

Brief summary: A bibliographic search carried out by the investigators demonstrated that there are few studies or data relating to the role and place of a State Registered Nurse (IDE) in a Mobile Palliative Care Team (EMSP) concerning the collection and the analysis of the needs expressed when formulating an evaluation request by the EMSP. The IDE collects, questions, analyzes needs and initiates an evaluation with the patient or, failing that, advises and/or redirects. This first necessary step before the overall evaluation led the investigators to question the autonomy of the IDE in an EMSP and to research what are the representations of an IDE in this role of collecting and analyzing needs. when making such a request?

The aim of this research is to explore the professional practices of nurses within other PMSCs in order to analyze them and move towards improving patient care.


Eligibility criteria: Inclusion criteria:

* State-certified nurse working in EMSP with intra- and extra-hospital activity in a CHRU or CHU.
* Subject having given their consent for the reuse of their data for the purposes of this research

Exclusion criteria:

* Subject having expressed opposition to participating in the study

Primary outcomes:
measure: Review of professional practices in Palliative Care
timeFrame: Study covers the period from February 9, 2023 to March 9, 2024
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de soins Palliatifs - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT02103920: A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Solid Tumor Cancer
Lead sponsor: National University Hospital, Singapore
Sponsor class: OTHER
First posted: 2014-04-04
Enrollment: 1400
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH.

Brief summary: The purpose of this study is to determine the expression of molecules involved in the glycine/serine pathway using immunohistochemistry in solid tumors. Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH will be obtained. Tissue microarray (TMA) is a high-throughput method of analysing large numbers of formalin-fixed, paraffin-embedded tumor at a minimal cost and effort. To analyse the expression of molecules of putative relevance to the glycine/serine pathway, (such as PSPH, PSAT1, SHMT1, and GLDC), TMA technology will be utilised as previously reported (Kristiansen, Zhang, Soong). Tissue arrays will be constructed from solid tumors including cancers of the colon/ rectum, lung, breast, cervix, ovary, endometrium, fallopian tube, prostate, kidney, testis, stomach, liver, brain and lymphoma. One hundred cases of each tumor type (subject to availability) will be stained using immunohistochemistry. Patient Identifiers will not be collected. Societal benefit in terms of knowledge gained to improve understanding of cancer. No direct risk to subjects as this is a retrospective study of archived pathological tumour samples.


Eligibility criteria: Inclusion Criteria:

* Patients with solid tumor cancer

Primary outcomes:
measure: Change the expression of molecules of putative relevance to the glycine/serine pathway
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Nationa University Hospital
Study officials:
References:
Clinical trial NCT06705920: Effect of Topical Active Oxygen Therapy on Surgical Site Wound Healing and Microbial Colonization
Official title: Effect of Topical Active Oxygen Therapy on Surgical Site Wound Healing and Microbial Colonization : Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1
Conditions: Patients Scheduled for Any Oral Surgical Flap Procedure That Require Suturing Will Be Included in This Study
Keywords: active oxygen
sutures
flap
microbiology
wound healing
Lead sponsor: Ain Shams University
Sponsor class: OTHER
Collaborators: name: British University In Egypt
First posted: 2024-11-26
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the antibacterial efficiency of oxygenated gel therapy on wound healing and microbiological colonization around surgical sutures

Detailed description: All the patients who will agree to participate in the study and who will sign the informed consent forms. Computer-generated randomization will be used to randomly divide the surgical sites into two groups. Control group: will receive no treatment. Study group: will receive active oxygen gel around suture. Patients scheduled for any oral surgical flap procedure that require suturing will be included in this study. After flap approximation, the surgical site will be sutured using 5-0 braided sutures. In the study group the gel will be applied over the suture and the patients will be instructed to apply the gel to the wound area and to the suture thread using a cotton swab, three times a day after brushing their teeth. Also, patients will be given instructions regarding their post-surgical care.

Eligibility criteria: Inclusion Criteria:

* Adult patients in a healthy systemic condition who required comprehensive dental treatment
* Both genders with age group \> 18 years old
* Patients should approve to deliver a signature to a written consent after study nature explanation.

Exclusion Criteria:

* Patients with severe smoking habits \>10 cig \\ day
* Pregnant females, decisional impaired individuals and handicapped patients
* Patients having poor oral hygiene or not wanting to carry out oral hygiene measures
* Patients on any medication affecting the soft tissue health (e.g., amlodipine, Cyclosporine A, hydantoin)

Primary outcomes:
measure: Post operative wound healing.
timeFrame: 2 weeks
Secondary outcomes:
measure: Microbiological assessment
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Al Sherouk
country: Egypt
facility: Faculty of Dentistry
state: Cairo
Study officials:
References:
Clinical trial NCT04166474: Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
Official title: Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hiv
Tuberculosis
Lead sponsor: University of Liverpool
Sponsor class: OTHER
Collaborators: name: Infectious Disease Institute, Kampala, Uganda
name: Desmond Tutu HIV Centre
First posted: 2019-11-18
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir when administered with standard, medium and high dose rifampicin.


Eligibility criteria: Inclusion Criteria:

* Ability to give informed consent prior to participation
* Willing and able to comply with all study requirements
* Receiving standard doses of RIF and INH
* HIV antibody negative
* Male or non-pregnant, non-breastfeeding female
* Study participation will not extend length of ATT by more than 4 weeks

Exclusion Criteria:

* \< 18 years
* Body weight \< 50 kg
* eGFR \< 60 mL/min
* Abnormal LFTs including ALT \> 2.5 ULN
* HIV antibody positive
* Non-standard TB regimen (containing RHZE)
* Women of childbearing age unless using effective contraception
* Family history of sudden cardiac death
* Prior history of cardiac disease that precludes the use of low dose digoxin
* Medical or psychiatric condition that might affect participation in the study based on investigator judgement
* Regular consumption of grapefruit or grapefruit juice
* ECG abnormalities that preclude the use of low dose digoxin (intermittent complete heart block, second degree AV block, supraventricular arrhythmia associated with conducting pathways, ventricular tachycardia or fibrillation)

Primary outcomes:
measure: Change in pharmacokinetic parameter Cmin of dolutegravir
timeFrame: Day 14, Day 28, Day 42, 5 weeks post anti-tuberculosis treatment
Secondary outcomes:
measure: Change in pharmacokinetic parameter AUC of dolutegravir
timeFrame: Day 14, Day 28, Day 42, 5 weeks post anti-tuberculosis treatment
measure: Change in pharmacokinetic parameter Cmax of dolutegravir
timeFrame: Day 14, Day 28, Day 42, 5 weeks post anti-tuberculosis treatment
measure: Number of participants with Grade 3 and above adverse events as assessed by DAIDS (corrected v2.1 July 2017)
timeFrame: From first dose of dolutegravir until study completion approximately 2 years
Other outcomes:
Locations:
city: Cape Town
country: South Africa
facility: Desmond Tutu Health Foundation
city: Kampala
country: Uganda
facility: Infectious Diseases Institute
Study officials:
affiliation: University of Liverpool
name: Saye Khoo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02430974: Chemotherapy of NSCLC With or Without Icotinib
Official title: Icotinib as Maintenance Treatment After Chemotherapy for Patients Undergoing Resection of EGRF Mutation-positive Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2015-04-30
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine kinase inhibitors (EGFR-TKI) confers a significant survival benefit. This study assessed the efficacy and safety of chemotherapy with or without icotinib in patients undergoing resection of stage IB to IIIA EGFR-mutated NSCLC.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing completely resection of EGRF mutation-positive NSCLC
* Staging ⅠB (with high risk factor) to ⅢA
* PS = 0 or 1
* Adequate hematological, biochemical and organ functions

Exclusion Criteria:

* Systemic anticancer therapy prior to surgery, other malignancies before or during the study, any unstable illness, women who were pregnant or lactating

Primary outcomes:
measure: Disease free survival
timeFrame: from the date of surgery until the date of first confirmed disease relapse or metastasis, assessed up to 5 years
Secondary outcomes:
measure: Number of Participants with Adverse Effects
timeFrame: duration of receiving chemotherapy and oral icotinib, expected to be 2.5 years
Other outcomes:
Locations:
Study officials:
affiliation: Nanfang Hospital, Southern Medical University
name: Kaican Cai, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Feng S, Wang Y, Cai K, Wu H, Xiong G, Wang H, Zhang Z. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. PLoS One. 2015 Oct 16;10(10):e0140794. doi: 10.1371/journal.pone.0140794. eCollection 2015.
Clinical trial NCT01085474: Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
Official title: Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Keywords: Asthma
Pharmaceutical intervention
Effect of a pharmaceutical intervention on the level of control of the asthmatic patient
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-03-12
Enrollment: 384
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 60 community pharmacies 10 patients per pharmacy

Brief summary: Measurement of disease control, treatment adherence and patient knowledge of his/her medication in patients that are receiving a pharmaceutical intervention compared with those patients who receive regular pharmaceutical care.


Eligibility criteria: Inclusion Criteria:

* Patients who have given their informed consent and expressed interest in participating in the study
* Asthmatic Patients

Exclusion Criteria:

* Patients with communication difficulties.
* Persons who obtain symbicort but not for their own use.
* Patients with other major diseases: Heart problems, COPD, EMPHYSEMA, lung cancer, AIDS.
* Patients with a respiratory infection.
* Patients with seasonal asthma.
* Pregnant women
* Patients who have previously participated in a health education study in asthma.

Primary outcomes:
measure: Evaluate the effect of the pharmaceutical intervention on the disease control, treatment adherence and patient knowledge of his/her medication using the MEF, treatment adherence and patient knowledge of the medication indicators.
timeFrame: First a Pilot in 3 months and then the final study in 6 months
Secondary outcomes:
measure: Compare disease control in patients who know their medication and those who doesn't.
timeFrame: First a Pilot in 3 months and then the final study in 6 months
measure: Compare disease control in patients who comply with their medication with those who doesn't.
timeFrame: First a Pilot in 3 months and then the final study in 6 months
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Research Site
city: Malaga
country: Spain
facility: Malaga
Study officials:
References:
citation: Garcia-Cardenas V, Sabater-Hernandez D, Kenny P, Martinez-Martinez F, Faus MJ, Benrimoj SI. Effect of a pharmacist intervention on asthma control. A cluster randomised trial. Respir Med. 2013 Sep;107(9):1346-55. doi: 10.1016/j.rmed.2013.05.014. Epub 2013 Jun 28.
Clinical trial NCT05492474: Cranial Ultrasound for Prehospital ICH Diagnosis
Official title: Cranial Ultrasound for Prehospital ICH Diagnosis (CUPID_EMS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intracerebral Hemorrhage
Acute Ischemic Stroke
Keywords: computed tomography (CT) scan
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2022-08-08
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Any patient deemed to have a stroke like presentation or possibility of brain hemorrhage in the clinical judgement of the EMS provider and a decision to transfer the patient to the nearest ED for further evaluation has been made
Primary purpose: SCREENING

Brief summary: To evaluate the feasibility of Emergency Medical System (EMS)-performed cPOCUS in the field for diagnosis of acute Intracerebral hemorrhage (ICH)

Detailed description: With the over-arching goal of achieving early diagnosis of Intracerebral hemorrhage (ICH) with cPOCUS, this study hypothesizes that (a) Emergency Medical System (EMS) personnel can competently perform cPOCUS in the field in a timely fashion in a large majority of stroke patients; (b) acquired POCUS images can be successfully and securely transmitted for a remote physician interpretation in a timely manner; and (c) cPOCUS will have a greater sensitivity and specificity than clinical scores as a screening tool for ICH identification in pre-hospital settings.

Eligibility criteria: Inclusion Criteria:

* Any patient deemed to have a stroke like presentation or possibility of brain hemorrhage in the clinical judgement of the Emergency Medical Services (EMS) provider and a decision to transfer the patient to the nearest Emergency Department (ED) for further evaluation has been made will be eligible for the study
* 18 years old or older
* transfer initiated by EMS to the ED for further evaluation
* performing ultrasound will not interfere with the care or triage as part of routine care

Exclusion Criteria:

* less than 18 years old
* incarcerate patients
* penetrating cranial/head trauma or scalp wound
* any patient where performing ultrasound will interfere with the care
* patients who decide not to be transported to ED

Primary outcomes:
measure: Success Rate for cPOCUS Exams
timeFrame: Year 1
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Aarti Sarwal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05553574: Inhibitory Capabilities Among Women With Eating Disorders
Official title: Inhibitory Capabilities Among Women With Eating Disorders
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Food Response
Food Stop
Food Response-inhibition
Lead sponsor: Hebrew University of Jerusalem
Sponsor class: OTHER
First posted: 2022-09-23
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of the study is to increase the flexible behavior toward food via inhibition training among restrained eaters. The expectation is that the train will increase food consumption, decrease food-related anxiety and affect implicit attitudes towards palatable foods


Eligibility criteria: Inclusion Criteria:

* Diagnosis of restrained eaters
* Adults ages 18-40

Exclusion Criteria:

* Current history or diagnosis of the following according to the criteria of the DSM-5:

Schizophrenia, schizoaffective disorder, hallucinations, unspecified psychotic disorder (NOS), a mental disorder due to acquired head injury, bipolar disorder, mental disorder as a result of organic development.

* Abuse or addiction to drugs and alcohol.

Primary outcomes:
measure: Main outcome
timeFrame: one hour
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hebrew university of Jerusalem
Study officials:
References:
Clinical trial NCT06848374: Dose Efficacy in Adhesive Capsulitis
Official title: Dose Comparison for the Treatment of Adhesive Capsulitis with Hydrodilatation and Corticosteroid Using an Anterior Approach Under Ultrasound-Guidance
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Adhesive Capsulitis of the Shoulder
Keywords: Frozen shoulder
hydrodilatation
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2025-02-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out if the treatment of adhesive capsulitis with 40 mg of methylprednisolone in combination with a hydrodilatation is comparable to 80 mg of methylprednisolone for pain reduction, improving shoulder mobility, and reducing side effects.

Researchers will enroll 40 people in this study which is taking place solely at the Toronto Rehabilitation Institute, University Avenue. This study should take approximately 12 months to complete and the results should be known in about 15 to 18 months. During this study, patients will receive an ultrasound guided shoulder hydrodilatation combined with corticosteroid after "randomized" into one of the groups (40 mg vs 80 mg). This is a double blind study as both patients and physicians would not know the group patient was randomized to.

Pain scores, Range of Motion and few other questionnaires wold be completed to track the response to the interventions at baseline prior to injection, four weeks after the procedure and 3 months after the procedure.


Eligibility criteria: Inclusion Criteria:

* \>18 years of age
* Diagnostic of adhesive capsulitis of the shoulder

Exclusion Criteria:

* Injection received in the affected shoulder \< 3 months ago (any kind)
* History of previous surgery in the affected shoulder
* Glenohumeral osteoarthritis more than mild on the xray
* Pregnancy
* Blood thinner (other than Aspirin 80 mg) or bleeding disorder
* Active infection (requiring antibiotic)
* Allergy to steroid or lidocaine
* Cognitive impairment
* Active litigation
* Inflammatory connective tissue disorder

Primary outcomes:
measure: Numeric Pain Scale
timeFrame: 3 months
Secondary outcomes:
measure: Shoulder Pain and Disability Index score
timeFrame: 3 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto Rehabilitation Institution
state: Ontario
Study officials:
References:
Clinical trial NCT06528574: Postoperative Pain After Activation of Irrigant
Official title: Incidence of Postoperative Pain After Activation of Irrigant With Apical Negative Pressure and Ultrasonics in Mandibular Molar Teeth With Irreversible Pulpitis: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pain
Lead sponsor: Cleveland Dental Institute
Sponsor class: OTHER
First posted: 2024-07-30
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to analyze the levels of pain after cleaning and shaping in individuals who are receiving root canal therapy using the IVAC irrigation approach, and those who are treated with ultrasonic irrigation techniques, negative pressure irrigation technique and traditional irrigation techniques.

PICOTS Question:

Does the new Dent's iVac irrigation protocol has an effect on reduction of postoperative pain

By enlisting at least 84 suitable individuals who are undergoing the identical endodontic procedure.

pain will be measures by assessing pain levels through a standardized numerical rate scale (NRS) at certain time intervals after root canal treatment, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours.


Eligibility criteria: Inclusion Criteria:

Males and females Age :20-50 Mandibular mature first molars with symptomatic acute pulpitis Medically free patients

Exclusion Criteria:

Pulp necrosis or apical periodontitis Periodontal disease Vertical root fracture Radiographic apical radiolucency

-

Primary outcomes:
measure: Numerical Pain Scale (NRS)
timeFrame: Preoperative, 6 hours, 12 hours, 24 hours, 48 hours and 72 hour post-procedure.
Secondary outcomes:
measure: Analgesics intake
timeFrame: 6 hours, 12 hours, 24 hours,48 hours and 72 hour post-procedure.
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Dental Institute
state: Ohio
Study officials:
affiliation: Cleveland Dental Institute
name: Ahmed A Hashem, PhD
role: STUDY_CHAIR
References: